Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis - Wikidata - wikimedia - TriplyDB

Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis

Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis

http://www.wikidata.org/entity/Q28480972

about

Eliminating the Neglected Tropical Diseases: Translational Science and New Technologies.Why the radiation-attenuated cercarial immunization studies failed to guide the road for an effective schistosomiasis vaccine: A review Eliminating Schistosomes through Vaccination: What are the Best Immune Weapons?Cytokine responses to the anti-schistosome vaccine candidate antigen glutathione-S-transferase vary with host age and are boosted by praziquantel treatment Serological screening of the Schistosoma mansoni adult worm proteome An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas Protection against Schistosoma mansoni infection using a Fasciola hepatica-derived fatty acid binding protein from different delivery systems Helminth Immunomodulation in Autoimmune Disease.Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults.Lipid core peptide targeting the cathepsin D hemoglobinase of Schistosoma mansoni as a component of a schistosomiasis vaccine.Schistosomiasis chemotherapy.The schistosome glutathione S-transferase P28GST, a unique helminth protein, prevents intestinal inflammation in experimental colitis through a Th2-type response with mucosal eosinophils.Human Schistosoma haematobium antifecundity immunity is dependent on transmission intensity and associated with immunoglobulin G1 to worm-derived antigens Immunology of human schistosomiasis.A Meta-Analysis of Experimental Studies of Attenuated Schistosoma mansoni Vaccines in the Mouse Model.Of monkeys and men: immunomic profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates.Protective immune responses against Schistosoma mansoni infection by immunization with functionally active gut-derived cysteine peptidases alone and in combination with glyceraldehyde 3-phosphate dehydrogenase.Identification of Antigenic Glycans from Schistosoma mansoni by Using a Shotgun Egg Glycan Microarray Glycoconjugates in host-helminth interactions Immunomodulation of TH2 biased immunity with mucosal administration of nanoemulsion adjuvant.Development of a schistosomiasis vaccine.Prevalence and intensity of urinary schistosomiasis among school children in the district of Niakhar, region of Fatick, Senegal.Determining the validity of hospital laboratory reference intervals for healthy young adults participating in early clinical trials of candidate vaccines.Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis.The Human Hookworm Vaccine.Diagnosis and treatment of schistosomiasis in children in the era of intensified control.Vaccination against helminth parasite infections.Clinical implications of recent findings in schistosome proteomics.The omic approach to parasitic trematode research-a review of techniques and developments within the past 5 years.Specific humoral response of hosts with variable schistosomiasis susceptibility.Immunomic approaches for antigen discovery of human parasites.Successful detection, expression and purification of the alternatively spliced truncated Sm14 antigen of an Egyptian strain of Schistosoma mansoni.Sm-p80-Based Schistosomiasis Vaccine: Preparation for Human Clinical Trials.Back to the future for antiparasite vaccines?The self-curing phenomenon of schistosome infection in rhesus macaques: insight from in vitro studies.Extracellular vesicles induce protective immunity against Trichuris muris.Metazoan Parasite Vaccines: Present Status and Future Prospects.

P2860

Q26765026-DEC5B775-7D3C-41DE-8927-B4A4FF5A517F Q26800061-BB0894AF-A7C0-422A-850A-5702F30D8F90 Q28081158-1B713A2D-F411-454C-953C-B6DD377F028B Q28538582-727A420C-DA92-4339-B381-899A3C9B15AC Q28541191-AB55D021-2CCD-4544-9062-C0B9569C0C85 Q28541675-13DA1CA4-C1E0-4478-A8AB-80BBAEE6356E Q28834543-01AF8713-F680-4571-BED3-5CB9A626ED02 Q33593313-0911632F-E430-404F-83C0-0A696D105029 Q33719126-1E1CB51A-3FE1-453C-9C07-1EA8885A8CFD Q34290786-AA1D5B31-C806-4409-AAF0-D5D8FCE50FFF Q34354490-F4687815-5826-4A8E-B751-5B560B3262DB Q34485066-1CE34B3F-A91D-400F-AC03-8A6469C6C786 Q34563567-FB442F91-2F2E-492E-8306-7F4B51FF029D Q34782228-F725BBEA-FAEF-42B6-8B4E-71AC903281CC Q35128551-871C7658-10D2-4378-8EF3-F3D22058BD77 Q35569944-5A96EE56-9857-449B-AE00-B05CA20BF8FF Q36323948-C8DD3B5C-DE17-41F8-BAA7-8E907CC0B20F Q36888540-402A5C65-91F6-4BB6-A6BE-23CF6AFF6D16 Q37126736-2F20EE19-F9EC-4538-B52C-07D3F5DA3A12 Q37130834-4613C701-6DB2-41C3-A7EF-30E8352C7FEB Q37350747-C22B6AF1-98CE-4607-AAFA-AFDF952A2150 Q37438796-30F4FB90-E512-4635-BFBD-D2A457C59D6C Q37530123-31991EA0-69A7-4556-9637-DEFD88A7E048 Q37694858-0AEC2E0B-BF93-4A5F-9B7B-8026CC0BFAC3 Q37694861-E0775930-A471-4EF6-A070-ADFE306B2DA4 Q37706375-72170F97-EF28-4B46-B474-090A51FD3A7E Q38152776-32551F88-50FD-4825-90C6-1CB668ECDBBB Q38194247-9CBE2018-F266-4521-99AD-5DCF9E7FD32D Q38630566-B9C57192-D7A6-4A13-B84A-4454585CBBFA Q38820297-B3BDD6F8-BDA2-4F16-A519-92532931C817 Q38978103-FC11E5CF-535B-405D-B78F-1DEAB6DC29FF Q38989213-48F8DDA6-4FB3-4453-9030-5AF6A58574D7 Q38996628-242D657A-CD6F-4F33-919A-8B7AD69E0C5D Q39014289-875453C3-98A7-4DCD-BF28-878B2ED47960 Q46559450-66AA4872-672C-4A66-9939-34C8DA533CF1 Q47294803-70E1FE94-2EDB-438C-AE3B-314C3A38C6F2 Q54216084-B36D328C-8792-4599-814F-CC9DBF4D3354 Q55024731-AE047669-DFBA-4B4C-B3CD-249FA821C340

P2860

Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis

http://www.wikidata.org/entity/Q28480972

description

2012 nî lūn-bûn

@nan

2012 թուականին հրատարակուած գիտական յօդուած

@hyw

2012 թվականին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

name

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@ast

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@en

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@nl

type

label

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@ast

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@en

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@nl

prefLabel

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@ast

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@en

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@nl

P1433

Q28480972-E2ADC933-68DE-4818-934A-1523F906D484

P1476

Q28480972-C1FCAD23-B89A-439B-8598-245CA84EBF4B

P2093

Q28480972-03F5A7B3-EC0B-4FBF-9626-2CA92EBCB28B

Q28480972-20121F43-6F16-45B0-A218-F4126CC44822

Q28480972-2588AA89-3680-4CFF-BBF1-9D2EFA9F2BD0

Q28480972-A233C631-DA3D-4EEC-B74B-F5EACDD8C022

Q28480972-C7A91503-59A4-4E90-9728-CC1DDDC7FD35

Q28480972-EAFDCC3F-3D5A-4A1C-8128-8F6B2525274B

Q28480972-F8C632A8-9C93-4A1D-8EB3-B8F865CE20DD

Q28480972-FA838E54-8840-4572-B6B2-6403878EEB0B

P275

Q28480972-3C2E26D5-A407-412B-807A-3B44C08070A9

P2860

Q28480972-0358543C-AF8A-47CF-B49F-A7A429BD8A16

Q28480972-1A47BCA4-85B8-4846-B900-5E7EAC480F3B

Q28480972-1E32798F-EB2C-4BC5-8FE6-9F555F6859B2

Q28480972-3180A717-30C9-4D9E-87DB-DCD467A2750B

Q28480972-386D6868-42A7-47BF-83A0-57BF29060899

Q28480972-469E63BA-2E6D-4D20-9D42-5E5E8107704F

Q28480972-4AFA8B64-A343-43E1-A828-64E5587D8DD5

Q28480972-4F207713-0B24-4819-A98B-5AB7F2D9F7E1

Q28480972-50851869-68E6-4C2C-86B3-7ADDF6DB502D

Q28480972-5D58C48A-CB3E-45F3-B449-0F8C7BDB5CD5

P304

Q28480972-A2722C7A-AAD0-4779-9FC0-34B7B696839F

P31

Q28480972-899961EC-D06E-41A8-8AAA-0F435716AD90

P3181

Q28480972-ABCDD295-A845-4E0A-B8D6-34DE5ADF0CCA

P356

Q28480972-ED065CEE-7FC3-4549-95F0-6A258DFCC7B7

P407

Q28480972-398C5809-CCF5-4B75-9D2F-98CB9A5135FA

P433

Q28480972-588C24BC-4D63-4BC9-9776-46FB6A035A71

P478

Q28480972-2BFADD7E-3A6B-4D0F-BF06-AB442FFB62C7

P50

Q28480972-522BB757-3F9F-4485-A10C-B43926B54180

Q28480972-A9435381-0F0F-40D8-97EF-7A98C1C1094C

P5008

Q28480972-96180BA2-BAAE-463E-B4E3-6F31CBD16738

P577

Q28480972-37A0485B-7116-4312-A731-60224504F67D

P5875

Q28480972-5693D21A-9616-4984-8C48-45D9D64573BC

P698

Q28480972-035AC564-FB31-4C31-900A-F1FA9AFD206F

P921

Q28480972-32412D08-986F-4C73-8955-A0BDCBA94893

Q28480972-8CC629E9-4930-456C-97B7-0D0B499E44B5

P932

Q28480972-960C7D70-7B43-4CA4-AAF6-7066B9F53D7A

P3181

P356

JOURNAL.PNTD.0001704

P1433

PLOS Neglected Tropical Diseases

P1476

Safety and immunogenicity of r ...... gainst urinary schistosomiasis

@en

P2093

André Capron

http://www.w3.org/2001/XMLSchema#string

Anne-Marie Schacht

http://www.w3.org/2001/XMLSchema#string

Christian Libersa

http://www.w3.org/2001/XMLSchema#string

Franck Remoué

http://www.w3.org/2001/XMLSchema#string

Gilles Riveau

http://www.w3.org/2001/XMLSchema#string

Hubert Vodougnon

http://www.w3.org/2001/XMLSchema#string

Joseph Martial

http://www.w3.org/2001/XMLSchema#string

Michel Thiry

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 2.5 Unported

P2860

Relationship of impairment of schistosome 28-kilodalton glutathione S-transferase (GST) activity to expression of immunity to Schistosoma mattheei in calves vaccinated with recombinant Schistosoma bovis 28-kilodalton GST

Prospects for a schistosome vaccine.

Praziquantel: an urgent and exciting challenge.

Schistosomes: the road from host-parasite interactions to vaccines in clinical trials.

Schistosoma mansoni 28-kDa glutathione S-transferase and immunity against parasite fecundity and egg viability. Role of the amino- and carboxyl-terminal domains.

Schistosomiasis vaccine:research to development.

Adjuvant properties of aluminum and calcium compounds.

Prospects for immunological control of schistosomiasis.

Development of Th 1- or Th 2-dominated immune responses: what about the polarizing signals?

An update on human Th1 and Th2 cells.

P304

e1704

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1324347

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PNTD.0001704

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Deplanque

P5008

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229157988

http://www.w3.org/2001/XMLSchema#string

P698

22802974

http://www.w3.org/2001/XMLSchema#string

P921

infectious disease

schistosomiasis

P932

3389022

http://www.w3.org/2001/XMLSchema#string